Cypher: Post-marketing study data

Data from the single-blind, Danish SORT-OUT IV trial in >2,600 patients showed that Cypher was non-inferior to Xience V on the primary endpoint of the composite rate of MACE at 9 months (5.3% vs. 4.9...